Vitro presents its new staining device incorporating state-of-the-art technology
 

• The device, designed and produced entirely in Spain, will be launched on the market in September 2023.
  


• It is designed to perform multiple techniques in the same instrument, including immunohistochemistry, immunofluorescence, in situ hybridization and histochemistry.
  


• Its advantages include robustness, flexibility, versatility, safety and high quality staining.
  

Madrid, 27 April 2023

At the 21st National Congress of the Spanish Society of Pathology (SEAP-IP) in Seville on 3-5 May, the Vitro company, specialists in marketing and producing in vitro reagents, platforms and diagnostic software and related services, will be presenting the first instrument capable of applying state-of-the-art technology, such a artificial intelligence, to anatomical pathology diagnosis.

Anatomical pathology diagnosis in Anatomical Pathology units is based on integrating existing clinical-pathological and morphological data with new solutions, incorporating the very latest technological advances into the diagnostic process.

In this context, Vitro, in conjunction with FIDETIA, part of the University of Seville, has created a new staining instrument, designed and produced entirely in Spain, which, thanks to the combination of various state-of-the-art technologies, optimises and improves the overall execution process of the above mentioned techniques.

According to Andrés Ballesteros Nobell, the Vitro Pathology CEO, “optimising and controlling the process with artificial intelligence helps reduce errors and provide more reliable diagnoses, thereby benefiting patients and improving the day-to-day work of lab professionals.”

Another advantage of the new staining device is that it is the first in the world to be able to perform immunohistochemistry, immunofluorescence, in situ hybridization and histochemistry techniques in the same instrument.

With the launch of this new device, Vitro is adding to its extensive portfolio of anatomical pathology products, offering laboratories a complete service to match the international leaders in the sector.

The device, which will be available on the market in September 2023, is especially designed for the study of solid tumours. As Ballesteros Nobell concludes, “We hope to provide our grain of sand to the fight against cancer, improving the diagnosis and treatment of patients who suffer from this disease.”